Shares of Insulet Corporation vaulted to $161.41 in after-hours trading Wednesday, capping a 16% three-day rally from last Monday's close of $138.97 — a level that sat near the stock's 52-week low. The catalyst: Deutsche Bank analyst Kieran Ryan initiated coverage with a Buy rating and a $190 price target , lending fresh institutional conviction to a stock that had shed more than half its value over the prior year. The firm set its target based on roughly 13 times Insulet's projected 2027 enterprise value to EBITDA — a measure of the company's operating profits — implying the stock still has 18% upside from here.

  • A Well-Timed Vote of Confidence Near Rock Bottom. Insulet's shares had touched a 52-week low of $140.63 on May 28 and declined 36.7% over the prior three months. Deutsche Bank's initiation landed when bearish sentiment was at its peak. The bank acknowledged headwinds from competition in tubeless insulin pumps and pharmacy channels, as well as concerns about GLP-1 weight-loss drugs potentially shrinking the diabetes device market — but argued those risks were already reflected in the stock's depressed valuation.

  • The Numbers Back the Bull Case — For Now. In Q1 2026, Insulet posted earnings of $1.30 per share (up from $0.50 a year earlier), revenue of $761.7 million (up 34%), and net income of $91.1 million (up 157%).

Management is guiding for 21–23% revenue growth in 2026, driven by adoption of its latest automated insulin pump and international expansion. That execution stood out in a quarter where many medtech peers guided cautiously.

  • Wall Street Is Overwhelmingly Bullish, Yet the Stock Hasn't Listened. Roughly 88% of analyst ratings on Insulet are Buys , with a mean price target of $237.56 — implying 63% upside. Yet the stock is still down over 50% from its 52-week high of $354.88. The disconnect suggests investors remain spooked by the GLP-1 threat and up to $50 million in non-recurring costs flagged by management, which triggered a 7%-plus selloff in early June.

  • Insiders Are Buying Alongside the Analyst. Director Elizabeth Weatherman purchased roughly 3,000 shares at about $144 in early June — the largest insider buy in three months.

Director Timothy Stonesifer also bought 2,790 shares on June 3. When executives spend their own money alongside a bullish initiation, it signals confidence beyond promotional spin.

The question now is whether Insulet's growth rate can outrun the GLP-1 narrative long enough for the stock to close the yawning gap between its price and where nearly every analyst says it should trade.